IBD (General)
Why IBD care must go beyond inflammation
In inflammatory bowel disease (IBD), clinical success is still too often defined by what happens in the clinic rather than what happens in people’s lives.
The Reality of Living with IBD
IBD is a lifelong, fluctuating condition that affects people at formative stages of life and stays with them for decades. Even when inflammation appears controlled, many people continue to live with fatigue, urgency, pain, anxiety, and a persistent sense of uncertainty. Daily life is shaped by adaptation: planning around toilets, conserving energy, avoiding social situations, and managing the constant background fear of deterioration.
And yet, much of this experience remains peripheral to how care is organised and assessed.
The Limits of Episodic, Clinic-Centred Care
IBD care is still largely structured around a binary view of disease activity: flare or remission. In practice, clinicians increasingly recognise a grey zone between these states. People may not meet the threshold for an acute flare, but their disease is not well controlled in any meaningful sense. Symptoms persist, confidence erodes, and quality of life steadily declines, even while clinical markers appear acceptable.
This state of poorly controlled disease is not an anomaly. It is a predictable consequence of a system that prioritises episodic measurement over longitudinal understanding.
Traditional definitions of “good care” in IBD rely heavily on biomarkers, endoscopy, and clinic-based assessments. These measures matter. They are essential for safe and effective treatment. But they capture only a narrow slice of the patient journey. They offer limited insight into what happens between appointments, where early signals of deterioration often emerge and where most of the work of living with IBD actually takes place.
As a result, care remains reactive by design. Patients are reviewed periodically and reassured when results look stable. Subtle changes in symptoms, coping strategies, or daily functioning may go unnoticed until they escalate into a crisis that forces intervention. By that point, opportunities for earlier, more proportionate support have often been missed.
Digital health has not consistently solved this problem. Many tools have focused on tracking, alerts, and data collection, operating on the assumption that more information will automatically lead to better outcomes. For patients, this can increase cognitive burden and anxiety. For clinicians, it can generate volume without context. Data is captured, but interpretation, prioritisation, and action are left unresolved.
The consequences are felt across the system. People are told their disease is “well controlled” while feeling unable to work normally, socialise confidently, or plan ahead. Clinicians are asked to make decisions without visibility into how patients are actually living over time. Health services absorb avoidable escalation and complexity. And outcomes that matter most to people with IBD remain under-recognised.
Designing Care Around Lived Experience
At Ampersand Health, this gap has shaped our work from the outset. Founded within the NHS and developed alongside clinicians and patients, we have seen repeatedly that prevention in IBD is not only pharmacological. It is behavioural, longitudinal, and deeply personal. The challenge is rarely a lack of data; it is a lack of support to interpret change, reduce uncertainty, and act earlier with confidence.
This is where the next generation of digital health needs to focus. The role of technology is not surveillance, and it is not simply automation. Its real value lies in reducing cognitive burden, helping people make sense of what they are experiencing, and supporting better conversations and decisions over time.
For clinicians, this offers better longitudinal visibility into patients’ lived experience. For patients, it reduces guesswork and isolation. And for health systems, it creates the conditions for earlier, more proportionate intervention.
More broadly, the implications extend beyond any single tool. If we want to improve outcomes in IBD and other long-term conditions, we need to rethink how success is defined. Quality of life, early deterioration, and sustained wellbeing must be treated as core objectives, not secondary considerations.
–
Clinical remission matters. But living well matters more. Recognising the difference, and designing care around it, is one of the most important opportunities we have to build more effective and sustainable long-term condition care.
